Navigation Links
DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Company's Melanoma Advisory Board
Date:3/5/2008

LA JOLLA, Calif., March 5 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Allan C. Halpern, MD, has joined DermTech's Melanoma Advisory Board. Dr. Halpern is Chief of Dermatology at Memorial Sloan-Kettering Cancer Center and widely recognized as an expert in the early detection and management of melanoma in high-risk individuals.

"We are delighted and honored to welcome Dr. Halpern to our Melanoma Advisory Board," said George Schwartz, CEO, DermTech. "Dr. Halpern is a world leader in the area of melanoma and strategies for improved diagnosis and prevention of this disease that, if identified early, has an extremely high cure rate. DermTech will clearly benefit from his significant experience as we move toward clinical trials of our novel, non-invasive molecular diagnostic product for melanoma early detection."

"I am looking forward to working with the company and the outstanding panel of dermatologists and melanoma experts already on this advisory board," said Allan Halpern, MD. Other Melanoma Advisory Board members include: Boris Bastian, MD, David Polsky, MD, PhD, and Harold S. Rabinovitz, MD.

Allan Halpern, MD, is a board-certified internist and dermatologist. In addition to his role as Chief of Dermatology at MSKCC, he is co-leader of the Center's Melanoma Disease Management Team, which incorporates the expertise of doctors in surgery, medical oncology, clinical immunology, dermatology, pathology, and radiation oncology to diagnose and treat melanoma. He pioneered the use of digital whole-body photography to assist in the detection of changing moles in patients with dysplastic nevi (large, irregular colored or shaped moles). Currently, his research is focused on epidemiologic (population-based) studies with a subset of this research devoted to the study of the genetic and environmental factors that influence the development of moles in children and adolescents. Dr. Halpern received his medical degree from the Albert Einstein College of Medicine in New York and completed his Dermatology residency at the Hospital of the University of Pennsylvania. He has presented and published extensively on melanoma detection.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR(TM) and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information visit http://www.dermtech.com.

Contacts:

DermTech

George Schwartz

CEO

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Radlink Names Allan Christensen Vice President of Technical Services
2. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
3. WorldHeart Appoints David Pellone Chief Financial Officer
4. Mediware Names Thomas K. Mann Chief Executive Officer
5. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
6. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
7. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
8. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
9. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
10. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... York, New York (PRWEB) , ... April 28, ... ... high-quality anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin ... cream provides the hydrating benefits of a moisturizer with the power of an ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... April 18, 2017 Viverae ® , a ... the integration of IBM ® Watson Campaign Automation, ... targeted communications for a personalized experience. Through digital engagement, ... their health in real time. The enhanced experience drives ... to members, wherever they are in their journey to ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology: